RS65211B1 - Bispecifična antitela protiv ceacam5 i cd47 - Google Patents

Bispecifična antitela protiv ceacam5 i cd47

Info

Publication number
RS65211B1
RS65211B1 RS20240190A RSP20240190A RS65211B1 RS 65211 B1 RS65211 B1 RS 65211B1 RS 20240190 A RS20240190 A RS 20240190A RS P20240190 A RSP20240190 A RS P20240190A RS 65211 B1 RS65211 B1 RS 65211B1
Authority
RS
Serbia
Prior art keywords
antibodies against
bispecific antibodies
against ceacam5
ceacam5
bispecific
Prior art date
Application number
RS20240190A
Other languages
English (en)
Inventor
Vanessa Buatois
Anja Seckinger
Dirk Hose
Original Assignee
Lamkap Bio Beta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Beta Ag filed Critical Lamkap Bio Beta Ag
Publication of RS65211B1 publication Critical patent/RS65211B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pens And Brushes (AREA)
  • Conversion Of X-Rays Into Visible Images (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20240190A 2020-12-18 2021-12-17 Bispecifična antitela protiv ceacam5 i cd47 RS65211B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20215766 2020-12-18
US202163135996P 2021-01-11 2021-01-11
EP21834934.8A EP4055055B1 (en) 2020-12-18 2021-12-17 Bispecific antibodies against ceacam5 and cd47
PCT/IB2021/061983 WO2022130348A1 (en) 2020-12-18 2021-12-17 Bispecific antibodies against ceacam5 and cd47

Publications (1)

Publication Number Publication Date
RS65211B1 true RS65211B1 (sr) 2024-03-29

Family

ID=79164846

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240190A RS65211B1 (sr) 2020-12-18 2021-12-17 Bispecifična antitela protiv ceacam5 i cd47

Country Status (16)

Country Link
US (2) US11753481B2 (sr)
EP (1) EP4055055B1 (sr)
JP (1) JP2024501809A (sr)
KR (1) KR20230121772A (sr)
AU (1) AU2021400227A1 (sr)
CA (1) CA3193210A1 (sr)
CL (1) CL2023001797A1 (sr)
CO (1) CO2023009100A2 (sr)
ES (1) ES2967381T3 (sr)
HR (1) HRP20240213T1 (sr)
IL (1) IL301701A (sr)
MX (1) MX2023007220A (sr)
PE (1) PE20231386A1 (sr)
PL (1) PL4055055T3 (sr)
RS (1) RS65211B1 (sr)
WO (1) WO2022130348A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019234576A1 (en) * 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
US20240002544A1 (en) * 2022-03-07 2024-01-04 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294372B1 (en) 1997-03-14 2001-09-25 University Of Victoria Innovation & Dev. Corp. Replication genes and gene products from small cryptic plasmids and methods for constructing controlled-replication plasmid vectors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005018669A1 (en) 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
WO2006023420A2 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
CN101370827B (zh) 2005-12-21 2015-10-14 麦克罗梅特股份公司 具有cea抗性的药物组合物
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
JP5357778B2 (ja) 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
EP3581588B1 (en) 2008-09-17 2022-06-15 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
MX2012003404A (es) 2009-09-22 2012-09-12 Volker Sandig Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
DK2606064T3 (en) 2010-08-16 2015-04-20 Novimmune Sa Methods for generating multispecific and multivalent antibodies
AU2012222463B9 (en) 2011-03-02 2017-05-25 Roche Glycart Ag CEA antibodies
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
WO2013088259A2 (en) 2011-10-19 2013-06-20 Novimmune S.A. Methods of purifying antibodies
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
WO2014087248A2 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EA201891502A1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
AU2016239683B2 (en) 2015-03-31 2022-02-03 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
TW201741340A (zh) 2016-05-09 2017-12-01 賽基公司 Cd47抗體及使用其之方法
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018098384A1 (en) 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
US11518810B2 (en) 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
CA3070519A1 (en) 2017-07-21 2019-01-24 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
WO2019234576A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47

Also Published As

Publication number Publication date
EP4055055C0 (en) 2023-11-22
CL2023001797A1 (es) 2024-02-09
PL4055055T3 (pl) 2024-04-15
US20220195067A1 (en) 2022-06-23
JP2024501809A (ja) 2024-01-16
US11753481B2 (en) 2023-09-12
CO2023009100A2 (es) 2023-08-18
EP4055055A1 (en) 2022-09-14
US20240101705A1 (en) 2024-03-28
PE20231386A1 (es) 2023-09-12
AU2021400227A9 (en) 2024-05-30
WO2022130348A1 (en) 2022-06-23
HRP20240213T1 (hr) 2024-04-26
AU2021400227A1 (en) 2023-04-27
MX2023007220A (es) 2023-08-25
CA3193210A1 (en) 2022-06-23
IL301701A (en) 2023-05-01
ES2967381T3 (es) 2024-04-30
KR20230121772A (ko) 2023-08-21
EP4055055B1 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
EP3802599C0 (en) BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
PL4055055T3 (pl) Przeciwciała dwuswoiste przeciwko ceacam5 i cd47
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
RS64645B1 (sr) Antitela protiv sars-cov-2
EP4219554A4 (en) HUMANIZED CD7-TARGETED ANTIBODY AND USE THEREOF
ZA201902118B (en) Novel cd47 monoclonal antibodies and uses thereof
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
IL290255A (en) Anti-ctla4/anti-pd-1 bispecific antibody and its uses
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
ZA202105150B (en) Conjugate comprising ligand and ceacam5 antibody fab fragment
EP3833693A4 (en) ANTI-PD-L1/ANTI-LAG3 BISPECIFIC ANTIBODIES AND THEIR USES
EP3919512A4 (en) HUMANIZED ANTI-Abeta MONOCLONAL ANTIBODY AND USE
EP4161964A4 (en) LAG3-BINDING ANTIBODIES AND USES THEREOF
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
EP4126938A4 (en) ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3
EP3688034A4 (en) BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
IL291049A (en) Anti-cd47 monoclonal antibody and use thereof
EP4112647A4 (en) ANTI-CD47/ANTI-PD-L1 ANTIBODIES AND ITS USES
IL289488A (en) Monoclonal antibodies that bind egfrviii and their use
IL307519A (en) Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
IL311039A (en) Anti-CD3 antibodies
EP4004054A4 (en) BISPECIFIC ANTI-HER2/ANTI-4-1BB ANTIBODY AND ITS USE
IL272733A (en) Monoclonal antibodies against pathological alpha-synuclein, and methods using same
IL307744A (en) Anti-CLDN4/anti-CD137 bispecific antibody